EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
EGFR Tests Market Report Overview
The EGFR Tests market size is valued at $45.9 million in 2023 and is expected to grow at a CAGR of more than 2% during 2023-2033. Epidermal Growth Factor Receptor gene (EGFR) Tests are carried out to detect mutations within this receptor gene in non-small cell lung cancer tumor cells; the outcome of which may determine if EGFR-targeted tyrosine kinase inhibitors such as gefitinib and erlotinib may be beneficial for treating non-small cell lung cancer (NSCLC).
EGFR Tests Market Outlook 2023-2033 ($ Million)
Buy the Full Report for More Insights on The EGFR Tests Market Forecast
Download a Free Sample Report
The EGFR tests market research report is built to visualize quantitative trends within the in vitro diagnostics therapeutic area. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing in-licensing and out-licensing strategies. Furthermore, the EGFR tests market model discusses the in-depth impact of COVID-19 on the EGFR tests market for 2020 and beyond.
Market Size (2023) | $45.9 million |
CAGR (2023-2033) | >2% |
Historic Period | 2015-2023 |
Forecast Period | 2023-2033 |
Key Segments |
|
Key Regions |
|
Key Companies |
|
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
EGFR Tests Market Dynamics
The market for EGFR tests will grow across all regions during the forecast period. This growth is being driven by several factors including a surge in lung cancer incidences, greater disease awareness, improved accessibility to EGFR-TKIs in emerging economies, and technological advancements. Furthermore, increasing and diversifying the use of targeted therapies, especially in combination with each other, will likely increase NGS use as the industry moves away from the established model of testing for single mutations only.
EGFR Tests Market Segments
The key segments in the EGFR Tests market are EGFR Immunohistochemistry Tests, EGFR Next Generation Sequencing (NGS) Tests, EGFR Nucleic Acid Amplification Tests (NAATs), EGFR Other Tests, and EGFR Sanger Sequencing Tests among others. In 2023, the EGFR Next Generation Sequencing (NGS) Tests segment led the market.
EGFR Tests Market Analysis by Segments, 2023 (%)
Buy the Full Report for More Insights into the EGFR Tests Market Segments
Download a Free Sample Report
EGFR Tests Market Segmentation by Regions
The key regions in the EGFR Tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2023, North America emerged as the leading regional segment with the US being the largest contributor to the regional market.
With rising lung cancer incidence and the increasing popularity of targeted therapies, EGFR testing is growing significantly in North America. NGS Tests led the market in the US and Canada whilst Sanger sequencing tests led the Mexican market.
EGFR Tests Market Analysis by Regions, 2023 (%)
Buy the Full Report for More Insights on Regions in the EGFR Tests Market
Download a Free Sample Report
EGFR Tests Market – Competitive Landscape
The key companies in the EGFR tests market are:
- Qiagen NV
- Thermo Fisher Scientific Inc
- Roche Diagnostics International Ltd
- Abbott Laboratories
- Agilent Technologies Inc
In 2023, Qiagen NV has the highest EGFR Tests market share and value, followed by Roche Diagnostics International Ltd.
EGFR Tests Market Analysis by Companies, 2023 (%)
Buy the Full Report for More Insights on Companies in the EGFR Tests Market
Download a Free Sample Report
Segments Covered in this Report
EGFR Tests Segment Outlook ($ Million, 2015-2033)
- EGFR Immunohistochemistry Tests
- EGFR Next Generation Sequencing (NGS) Tests
- EGFR Nucleic Acid Amplification Tests (NAATs)
- EGFR Other Tests
- EGFR Sanger Sequencing Tests
EGFR Tests Regional Outlook ($ Million, 2015-2033)
- Asia-Pacific
- Europe
- Middle East and Africa
- North America
- South and Central America
Key Inclusions of the market model are –
Currently marketed EGFR tests market and evolving competitive landscape –
- Insightful review of the key industry trends.
- Annualized total EGFR tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional, and Country level market specific insights –
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the EGFR tests market.
- Competitive dynamics insights and trends provided for the EGFR tests market.
Understand the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, Panagene Inc, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
- CMO executives who must have deep understanding of the EGFR Tests marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to –
- Understand the impact of COVID-19 on EGFR Tests.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving EGFR Tests.
- Generate revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the EGFR Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific EGFR Tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Qiagen NV
Agilent Technologies Inc
Illumina Inc
Thermo Fisher Scientific Inc
Abbott Laboratories
NimaGen BV
Mesa Laboratories Inc
New England Biolabs Inc
Amoy Diagnostics Co Ltd
HLB PanaGene Co Ltd
Frequently asked questions
-
What was the EGFR Tests market size in 2023?
The EGFR Tests market size was valued at $45.9 million in 2023.
-
What will the EGFR Tests market growth rate be during the forecast period?
The EGFR Tests market is expected to grow at a CAGR of more than 2% during 2023-2033.
-
Which segment accounted for the highest share of the EGFR Tests market?
In 2023, the EGFR Next Generation Sequencing (NGS) Tests segment led the market.
-
Which region dominated the EGFR Tests market share?
North America was the largest regional segment of the EGFR Tests market in 2023.
-
Which are the leading companies in the EGFR tests market leader?
The key companies in the EGFR tests market are Qiagen NV, Roche Diagnostics International Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Agilent Technologies Inc, Agena Bioscience Inc, NimaGen BV, and Amoy Diagnostics Co Ltd among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.